Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11

Medicinal Product Interactions – Ritonavir with Protease Inhibitors Co-administered Dose of Co- Dose of Medicinal Product AUC Cmin Medicinal Product administered NORVIR Assessed Medicinal (mg) Product (mg) Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold 1 Atazanavir ↑ 2 fold ↑ 3-7 fold Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg once daily in treatment experienced patients. For further information, physicians should refer to the SmPC for atazanavir. Darunavir 600, single 100 q12h Darunavir ↑ 14 fold Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than 100 mg twice daily have not been studied with darunavir. For further information, refer to the SmPC for darunavir. Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold fold Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily 10 have not been studied with fosamprenavir. For further information, physicians should refer to the SmPC for fosamprenavir. Indinavir 800 100 q12h Indinavir2 ↑ 178% ND q12h Ritonavir ↑ 72% ND Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of nephrolithiasis may be increased. Nelfinavir 1250 100 q12h Nelfinavir ↑ ND q12h 20to39% Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. Tipranavir 500 200 q12h Tipranavir ↑ 11 fold ↑ 29 fold q12h Ritonavir ↓ 40% ND Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of the combination. For further information, physicians should refer to the SmPC for tipranavir. ND: Not determined. 1. Based on cross-study comparison to 400 mg atazanavir once daily alone. 2. Based on cross-study comparison to 800 mg indinavir three times daily alone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 03a194213ac89748c50cfb4b51554f8455df8df904ff2077009223828e61e82e · Zeichen 2655–7456 im Abschnitt

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43

HOS-086399 · Präparat HOS-083284

Co- Dose of Co- Dose of Medicinal Product AUC Cmin administered administered NORVIR Assessed Medicinal Medicinal Product (mg) Product (mg) Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold 1 Atazanavir ↑ 2 fold ↑ 3-7 fold Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg once daily in treatment experienced patients. For further information, physicians should refer to the SmPC for atazanavir. Darunavir 600, single 100 q12h Darunavir ↑ 14 fold Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than 100 mg twice daily have not been studied with darunavir. For further information, refer to the SmPC for darunavir. Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold fold Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily have not been studied with fosamprenavir. For further information, physicians should refer to the SmPC for fosamprenavir. Indinavir 800 q12h 100 q12h Indinavir2 ↑ 178% ND Ritonavir ↑ 72% ND Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of nephrolithiasis may be increased. Nelfinavir 1250 q12h 100 q12h Nelfinavir ↑ ND 20to39% Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. Tipranavir 500 q12h 200 Tipranavir ↑ 11 fold ↑ 29 fold q12h Ritonavir ↓ 40% ND Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of the combination. For further information, physicians should refer to the SmPC for tipranavir. ND: Not determined.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d5308747ba178c6ebd0e34322c465d7122d5458d70aff134d17f324382a8fc16 · Zeichen 2732–7211 im Abschnitt

Wechselwirkungen · Viramune

Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-088096 · Präparat HOS-083615

Fosamprenavir Amprenavir AUC  0.67 It is not recommended to co- 1 400 mg BID (0.55-0.80) administer fosamprenavir and Amprenavir Cmin  0.65 Viramune if fosamprenavir is not (0.49-0.85) co-administered with ritonavir (see Amprenavir Cmax  0.75 section 4.4). (0.63-0.89)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 4aa0db0ef4f3341ed440468fc01b765e9c7d5f0af16ee8980cfb5f148a9b0f43 · Zeichen 7414–7889 im Abschnitt

Wechselwirkungen · Viramune

Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10–11

HOS-088098 · Präparat HOS-083615

10 Fosamprenavir/ritonavir Amprenavir AUC  0.89 Fosamprenavir/ritonavir and 700/100 mg BID (0.77-1.03) Viramune can be co-administered Amprenavir Cmin  0.81 without dose adjustments (0.69-0.96) Amprenavir Cmax  0.97 (0.85-1.10)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage bfbfe45b93be9ebc394b0c89703ec2150b377802a50f01edc1848f3669c47163 · Zeichen 8135–8528 im Abschnitt

Wechselwirkungen · Viramune

Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 35

HOS-088194 · Präparat HOS-083615

Fosamprenavir Amprenavir AUC  0.67 It is not recommended to co- 1 400 mg BID (0.55-0.80) administer fosamprenavir and Amprenavir Cmin  0.65 Viramune if fosamprenavir is not (0.49-0.85) co-administered with ritonavir (see Amprenavir Cmax  0.75 section 4.4). (0.63-0.89)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 59ea8b49e42286e13a7691b99227f96872e505beb808469fa50ae61f3e922b7f · Zeichen 7648–8129 im Abschnitt

Wechselwirkungen · Viramune

Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 35

HOS-088196 · Präparat HOS-083615

Fosamprenavir/ritonavir Amprenavir AUC  0.89 Fosamprenavir/ritonavir and 700/100 mg BID (0.77-1.03) Viramune can be co-administered Amprenavir Cmin  0.81 without dose adjustments (0.69-0.96) Amprenavir Cmax  0.97 (0.85-1.10)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage dcefb192fd504181f1f7f7800988cdba35010eae61fe5df1e2b48750e4e05cad · Zeichen 8332–8718 im Abschnitt

Wechselwirkungen · Viramune

Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 60

HOS-088288 · Präparat HOS-083615

Fosamprenavir Amprenavir AUC  0.67 It is not recommended to co- 1 400 mg BID (0.55-0.80) administer fosamprenavir and Amprenavir Cmin  0.65 Viramune if fosamprenavir is not (0.49-0.85) co-administered with ritonavir (see Amprenavir Cmax  0.75 section 4.4). (0.63-0.89)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 4aa0db0ef4f3341ed440468fc01b765e9c7d5f0af16ee8980cfb5f148a9b0f43 · Zeichen 7734–8209 im Abschnitt

Wechselwirkungen · Viramune

Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 60–61

HOS-088290 · Präparat HOS-083615

60 Fosamprenavir/ritonavir Amprenavir AUC  0.89 Fosamprenavir/ritonavir and 700/100 mg BID (0.77-1.03) Viramune can be co-administered Amprenavir Cmin  0.81 without dose adjustments (0.69-0.96) Amprenavir Cmax  0.97 (0.85-1.10)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 60f84f87a6d621df1cb81c6e63ab92965edd2defc29d2327752934a5e86cc0c3 · Zeichen 8455–8848 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12

HOS-108852 · Präparat HOS-093083

(inhibition of CYP3A enzymes) HIV CCR5 – antagonist Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Due to CYP3A inhibition by Kaletra 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ ritonavir Fosamprenavir: Co-administration of increased (700/100 mg BID) Amprenavir concentrations are doses of fosamprenavir (1400 mg significantly reduced. BID) with Kaletra oral solution (Lopinavir/ritonavir (533/133 mg BID) to protease 400/100 mg BID) inhibitor-experienced patients resulted in a higher incidence of or gastrointestinal adverse events and elevations in triglycerides with the Fosamprenavir (1400 mg combination regimen without BID) increases in virological efficacy, when compared with standard (Lopinavir/ritonavir doses of fosamprenavir/ritonavir. 533/133 mg BID) Concomitant administration of these medicinal products is not recommended. Tipranavir/ritonavir Lopinavir: Concomitant administration of (500/100 mg BID) AUC: ↓ 55% these medicinal products is not Cmin: ↓ 70% recommended. Cmax: ↓ 47% Acid reducing agents Omeprazole (40 mg QD) Omeprazole: ↔ No dose adjustment necessary

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) raltegravir (HOS-086187) fosamprenavir (HOS-086182) tipranavir (HOS-086184) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0b87fdd109f79a80601e3c574f5e18fed07b1789a2ca7f01d2eafaba29d23dc3 · Zeichen 4995–7833 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48

HOS-109004 · Präparat HOS-093083

(inhibition of CYP3A enzymes) HIV CCR5 – antagonist Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Kaletra Due to CYP3A inhibition by 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ Fosamprenavir: Co-administration of increased doses ritonavir (700/100 mg Amprenavir concentrations are of fosamprenavir (1400 mg BID) BID) significantly reduced. with Kaletra oral solution (533/133 mg BID) to protease inhibitor-experienced patients

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) raltegravir (HOS-086187) fosamprenavir (HOS-086182)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f782d1ab1c57001581096637b1440b57b3cb9dd3d00bfd730e7f8085e3a57bae · Zeichen 5188–6569 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48–49

HOS-109005 · Präparat HOS-093083

48 (Lopinavir/ritonavir resulted in a higher incidence of 400/100 mg BID) gastrointestinal adverse events and elevations in triglycerides with the or combination regimen without increases in virological efficacy, Fosamprenavir when compared with standard doses (1400 mg BID) of fosamprenavir/ritonavir. Concomitant administration of these (Lopinavir/ritonavir medicinal products is not 533/133 mg BID) recommended. Kaletra must not be administered once daily in combination with amprenavir. Tipranavir/ritonavir Lopinavir: Concomitant administration of these (500/100 mg BID) AUC: ↓ 55% medicinal products is not Cmin: ↓ 70% recommended. Cmax: ↓ 47% Acid reducing agents Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary QD) Lopinavir: ↔ Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary single dose) Alpha1 adrenoreceptor antagonist Alfuzosin Alfuzosin: Concomitant administration of Due to CYP3A inhibition by Kaletra and alfuzosin is contra- lopinavir/ritonavir, concentrations indicated (see section 4.3) as of alfuzosin are expected to alfuzosin-related toxicity, including increase. hypotension, may be increased. Analgesics Fentanyl Fentanyl: Careful monitoring of adverse effects Increased risk of side-effects (notably respiratory depression but (respiratory depression, sedation) also sedation) is recommended when due to higher plasma fentanyl is concomitantly concentrations because of administered with Kaletra. CYP3A4 inhibition by lopinavir/ritonavir. Antianginal Ranolazine Due to CYP3A inhibition by The concomitant administration of lopinavir/ritonavir, concentrations Kaletra and ranolazine is of ranolazine are expected to contraindicated (see section 4.3). increase.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) amprenavir (HOS-086183) ranitidine (HOS-085660) fentanyl (HOS-086196) fosamprenavir (HOS-086182) ranolazine (HOS-086141) tipranavir (HOS-086184) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 36be30eaedda7aebc321ed321c96a33a8b5f0e47dfdc414ad4d6358ff3954c0c · Zeichen 6614–9803 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83–84

HOS-109078 · Präparat HOS-093083

83 Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Due to CYP3A inhibition by Kaletra 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ Fosamprenavir: Co-administration of increased ritonavir (700/100 mg Amprenavir concentrations are doses of fosamprenavir (1400 mg BID) significantly reduced. BID) with Kaletra oral solution (533/133 mg BID) to protease (Lopinavir/ritonavir inhibitor-experienced patients 400/100 mg BID) resulted in a higher incidence of gastrointestinal adverse events and or elevations in triglycerides with the combination regimen without Fosamprenavir increases in virological efficacy, (1400 mg BID) when compared with standard doses of fosamprenavir/ritonavir. (Lopinavir/ritonavir Concomitant administration of these 533/133 mg BID) medicinal products is not recommended. Kaletra must not be administered once daily in combination with amprenavir. Tipranavir/ritonavir Lopinavir: Concomitant administration of these (500/100 mg BID) AUC: ↓ 55% medicinal products is not Cmin: ↓ 70% recommended. Cmax: ↓ 47% Acid reducing agents Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary QD) Lopinavir: ↔ Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary single dose) Alpha1 adrenoreceptor antagonist Alfuzosin Alfuzosin: Concomitant administration of Due to CYP3A inhibition by Kaletra and alfuzosin is contra- lopinavir/ritonavir, concentrations indicated (see section 4.3) as of alfuzosin are expected to alfuzosin-related toxicity, including increase. hypotension, may be increased.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) ranitidine (HOS-085660) raltegravir (HOS-086187) fosamprenavir (HOS-086182) tipranavir (HOS-086184) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 262bfc7747e8af6a0bc31322576cc9f33731bdf23847197000d08285e923bde2 · Zeichen 5337–8975 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 6

HOS-114232 · Präparat HOS-094063

Fosamprenavir Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) fosamprenavir (HOS-086182)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 0ebcc7bba6e41e3bfce088579434fd8e80ff5d1ebff37128ec5074a629c92d75 · Zeichen 1366–1656 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 6–7

HOS-114233 · Präparat HOS-094063

6 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the 1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 days) by 21 % and 23 %, respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 21c78bafde5f8a4c6732f07d7286d0b547d28921f9c6886981bab736231d3a54 · Zeichen 1710–2022 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 24

HOS-114284 · Präparat HOS-094063

Fosamprenavir Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the 1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %, respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b5bbce510ddb458a7317b9f10c586066a3d42da77e8f20dcec5a31067ba748a9 · Zeichen 1366–1966 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 47

HOS-114339 · Präparat HOS-094063

Fosamprenavir Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the 1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %, respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b5bbce510ddb458a7317b9f10c586066a3d42da77e8f20dcec5a31067ba748a9 · Zeichen 1768–2368 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 71

HOS-114391 · Präparat HOS-094063

Fosamprenavir Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the 1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %, respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b5bbce510ddb458a7317b9f10c586066a3d42da77e8f20dcec5a31067ba748a9 · Zeichen 1425–2025 im Abschnitt

Wechselwirkungen · Celsentri

CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-118462 · Präparat HOS-094825

Fosamprenavir/ritonavir Maraviroc AUC12: ↑ 2.49 Concomitant use is not 700 mg/100 mg BID Maraviroc Cmax: ↑ 1.52 recommended. Significant (maraviroc 300 mg BID) Maraviroc C12: ↑ 4.74 reductions in amprenavir Cmin observed may result Amprenavir AUC12: ↓ 0.65 in virological failure in Amprenavir Cmax: ↓ 0.66 patients Amprenavir C12: ↓ 0.64

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1db1f8ce99132149e5de7ca4def48df5a8c75d3e98f57af9b3690710f0048433 · Zeichen 11233–11810 im Abschnitt

Wechselwirkungen · Celsentri

CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-118465 · Präparat HOS-094825

NNRTI + PI Efavirenz 600 mg QD + Maraviroc AUC12: ↑ 2.53 CELSENTRI dose should lopinavir/ritonavir Maraviroc Cmax: ↑ 1.25 be decreased to 150 mg 400mg/100 mg BID Efavirenz, lopinavir/ritonavir twice daily when (maraviroc 300 mg BID) concentrations not measured, no co-administered with effect expected. efavirenz and a PI (except Efavirenz 600 mg QD + Maraviroc AUC12: ↑ 5.00 tipranavir/ritonavir where saquinavir/ritonavir Maraviroc Cmax: ↑ 2.26 the dose should be 600 mg 1000 mg/100 mg BID Efavirenz, saquinavir/ritonavir twice daily). (maraviroc 100 mg BID) concentrations not measured, no effect expected. Concomitant use of Efavirenz and Not studied. Based on the extent of CELSENTRI and atazanavir/ritonavir or inhibition by atazanavir/ritonavir or fosamprenavir/ritonavir is darunavir/ritonavir darunavir/ritonavir in the absence of not recommended. efavirenz, an increased exposure is expected.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage d690124f380d2a4e2a5c2f78bde41fd453b3cc8e78f11838b432b45d3290bf33 · Zeichen 11961–13173 im Abschnitt

Wechselwirkungen · Celsentri

CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11

HOS-118466 · Präparat HOS-094825

10 Etravirine and Maraviroc AUC12: ↑ 3.10 CELSENTRI dose should darunavir/ritonavir Maraviroc Cmax: ↑ 1.77 be decreased to 150 mg (maraviroc 150 mg BID) twice daily when Etravirine AUC12: ↔ 1.00 co-administered with Etravirine Cmax: ↔ 1.08 etravirine and a PI. Etravirine C12: ↓ 0.81 Concomitant use of Darunavir AUC12: ↓ 0.86 CELSENTRI and Darunavir Cmax: ↔ 0.96 fosamprenavir/ritonavir is Darunavir C12: ↓ 0.77 not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage a57c8c01f9dcf834aa2f4b4cc59c3d274cf395ca1d07640063148f1c61905525 · Zeichen 13221–14057 im Abschnitt

Quellenpassagen (66)

Wechselwirkungen · Norvir

Wechselwirkungen · Norvir

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Celsentri

Wechselwirkungen · Celsentri

Wechselwirkungen · Celsentri